View Future GrowthVaxil Bio 과거 순이익 실적과거 기준 점검 3/6Vaxil Bio의 연간 평균 수익은 53.5%였으며, Biotechs 산업의 수익은 연간 33.8% 증가했습니다.핵심 정보53.53%순이익 성장률57.03%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률38.17%순이익률n/a최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 05Vaxil Bio Ltd. announced that it has received CAD 0.14 million in fundingOn December 4, 2025, Vaxil Bio Ltd. closed the transaction. The company issued 1,244,441 units at a price CAD 0.1125 per Unit to raise gross proceeds of up to CAD 139,999.6125. Each warrant is exercisable, at any time prior to December 2, 2030. In accordance with applicable Canadian securities law, the securities issued pursuant to the Private Placement are subject to a four month and one day hold period expiring on April 3, 2026. The company compensated certain finders by payment of finders’ fees in the aggregate amount of CAD 11,200 and the issuance of an aggregate of 99,555 finders’ warrants. The finders’ warrants have identical terms to those of the warrants.공시 • Dec 04Vaxil Bio Ltd. Announces Board ChangesVaxil Bio Ltd. announces that Mr. Ari Kellen and Mr. Shawn Langer have resigned from the Company’s Board of Directors, effective immediately. Also effective immediately, the Company announces the appointment of Mr. Simon Igelman to the Company’s board. Mr. Igelman is a corporate transactional lawyer. His practice focuses on corporate finance and mergers and acquisitions, as well as providing advice on structured finance and capital markets mandates. Mr. Igelman has represented private and public companies on a variety of transactions, including private placements of equity and debt securities, securitizations in a variety of asset classes, public and private acquisitions and general corporate and commercial law matters.공시 • Oct 30Vaxil Bio Ltd. announced that it expects to receive CAD 0.35 million in fundingVaxil Bio Ltd. announced a non brokered private placement to issue 2,456,140 units at an issue price of CAD 0.1425 for the proceeds of CAD 350,000 on October 29, 2025. Each Unit will consist of one common share of the Company ("Shares") and one common share purchase warrant of the Company ("Warrants"). Each Warrant will entitle the holder to acquire one Share at a price of CAD 0.19 per Share for a period of five years following the closing of the Offering. The closing of the Offering is subject to a number of conditions, including but not limited to, approval by the TSX Venture Exchange of the Offering. The Company expects the Offering to close on or around November 14, 2025. On the closing of the Offering, the Company has agreed to pay certain finders a cash commission of up to 8% of the gross proceeds of the Offering and non-transferrable Warrants. The Units, the Shares and Warrants comprising the Units and the Finders' Warrants will be subject to a hold period of four months and one day from their date of issue in accordance with applicable securities laws.공시 • Apr 04Vaxil Bio Ltd. Announces Appointment of Daniel Bloch to the Audit CommitteeVaxil Bio Ltd. announced the Mr. Daniel Bloch, a current director of the Company has joined the audit committee, effective immediately. The audit committee now comprises Dr. Ari Kellen, Dr. Shawn Langer and Mr. Daniel Bloch, all independent directors. The board of directors remains unchanged, and comprises Mr. Gadi Levin (Chairperson and CEO), Dr. Ari Kellen (independent director), Dr. Shawn Langer (independent director) and Mr. Daniel Bloch (independent director).공시 • Jan 17Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. On August 20, 2024, the companies entered into an amalgamation agreement pursuant to which Vaxil will acquire all of the issued and outstanding securities of Green Data in a reverse merger transaction. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data. Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on January 16, 2025.공시 • Oct 07Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024.공시 • May 28Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data.공시 • Mar 06Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI. Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on March 4, 2024.공시 • Jan 11Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI.공시 • Aug 03+ 1 more updateVaxil Bio Ltd. Announces CFO ChangesVaxil Bio Ltd. announced, effective July 31, 2023, in order to reduce costs and preserve cash, Dr. Yuval Avnir, the Company’s CEO will be replaced by Mr. Gadi Levin, the Company’s current chairperson of the board and CFO. The Company further announces, effective July 31, 2023, the appointment of Mr. Alan Rootenberg, as the Company’s CFO. Mr. Rootenberg will be replacing Mr. Gadi Levin, who transitions from the CFO position to the CEO position. Mr. Rootenberg is a chartered professional accountant who has served as the Chief Financial Officer of a number of publicly traded companies listed on the NASDAQ, TSX, TSXV and CSE. These companies include biotechnology, mineral exploration, service technologies and cannabis research companies. He has also served as a director of a number of publicly traded companies. Mr. Rootenberg has a Bachelor of Commerce degree from the University of the Witwatersrand in Johannesburg, South Africa and received his CPA designation in Ontario, Canada.공시 • Jan 05Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOXVAXIL BIO LTD. provided an update on the results of in vivo efficacy study for licensed P-Esbp-DOX, a novel anti-cancer drug, first disclosed in press release from October 12, 2021. Vaxil, together with Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev (BGU), have demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). The results of the current in vivo experiment, along with the previous in vivo experiments suggests that P-Esbp-DOX which combines the safe HPMA polymer, the high affinity E-selectin targeting peptide, and the commonly used chemotherapeutic drug doxorubicin, is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer. P-Esbp-DOX is an HPMA (N-(2-hydroxypropyl methacrylamide)) polymer conjugated with a high-affinity E-selectin-binding peptide and with the cytotoxic drug doxorubicin (DOX). Targeting E-selectin is relevant to diseases with inflammatory component and cancer, since E-selectin is expressed exclusively on inflamed blood vessels and play an important role in the development of inflammation, cancer and supports metastatic spread of cancer. Prof. Ayelet David’s previous work in cancer research demonstrated that a single dose therapy of P-Esbp-DOX is effective in decreasing the rate of tumor growth and prolonging the survival of mice bearing primary Lewis lung carcinoma (3LL) tumors and established melanoma (B16-F10) lung metastases. In the experiment, four groups of mice were treated, four days post intrasplenic inoculation of CT26 colorectal cancer cells, with a single dose of either P-Esbp-DOX or P-DOX (15 mg/kg DOX equivalence), or free DOX (8 mg/kg), or saline. The findings confirm the significant effectiveness of a single dose of P-Esbp-DOX over other treatments in mice with detected CRC liver metastases: The number of surviving mice at day 85 was: 3/7 (43%) for P-Esbp-DOX, 1/6 (17%) for free DOX, and 0/6 for P-DOX and saline. The survival medians were: 63 days for P-Esbp-DOX, 36.5 days for P-DOX, 30 days for free DOX, and 35 days for saline (p=0.003 for P-Esbp-DOX vs. control P-DOX). P-Esbp-DOX was well-tolerated at the dose administered, with no weight loss observed post treatment. In summary, this experiment, coupled with previous work, continues to demonstrate the important role this novel therapeutic approach could play in cancer at all stages. Vaxil is pursuing all necessary steps to initiate human clinical trials as soon as possible. As previously disclosed in the Company's press release from August 28, 2019, the Company entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the Company will pay BGU a royalty on sales.매출 및 비용 세부 내역Vaxil Bio가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:VXLL.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Dec 25010030 Sep 25000030 Jun 25000031 Mar 25000031 Dec 24000030 Sep 24000030 Jun 24000031 Mar 24000031 Dec 23000030 Sep 23000030 Jun 230-10031 Mar 230-10031 Dec 220-10030 Sep 220-10030 Jun 220-10031 Mar 220-10031 Dec 210-10130 Sep 210-11130 Jun 210-11131 Mar 210-11131 Dec 200-11130 Sep 200-11130 Jun 200-10131 Mar 200-10131 Dec 190-10130 Sep 190-10130 Jun 190-10131 Mar 190-10131 Dec 180-10130 Sep 180-11130 Jun 180-11131 Mar 180-11131 Dec 170-21130 Sep 170-21130 Jun 170-21131 Mar 170-21131 Dec 160-51130 Sep 160-41030 Jun 160-41031 Mar 160-41031 Dec 150-11030 Sep 150-210양질의 수익: VXLL.F의 비현금 수익 수준이 높습니다.이익 마진 증가: VXLL.F는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VXLL.F는 지난 5년 동안 흑자전환하며 연평균 53.5%의 수익 성장을 기록했습니다.성장 가속화: VXLL.F는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: VXLL.F는 지난해 흑자전환하여 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VXLL.F의 자본 수익률(38.2%)은 높음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 19:22종가2026/05/04 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vaxil Bio Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 05Vaxil Bio Ltd. announced that it has received CAD 0.14 million in fundingOn December 4, 2025, Vaxil Bio Ltd. closed the transaction. The company issued 1,244,441 units at a price CAD 0.1125 per Unit to raise gross proceeds of up to CAD 139,999.6125. Each warrant is exercisable, at any time prior to December 2, 2030. In accordance with applicable Canadian securities law, the securities issued pursuant to the Private Placement are subject to a four month and one day hold period expiring on April 3, 2026. The company compensated certain finders by payment of finders’ fees in the aggregate amount of CAD 11,200 and the issuance of an aggregate of 99,555 finders’ warrants. The finders’ warrants have identical terms to those of the warrants.
공시 • Dec 04Vaxil Bio Ltd. Announces Board ChangesVaxil Bio Ltd. announces that Mr. Ari Kellen and Mr. Shawn Langer have resigned from the Company’s Board of Directors, effective immediately. Also effective immediately, the Company announces the appointment of Mr. Simon Igelman to the Company’s board. Mr. Igelman is a corporate transactional lawyer. His practice focuses on corporate finance and mergers and acquisitions, as well as providing advice on structured finance and capital markets mandates. Mr. Igelman has represented private and public companies on a variety of transactions, including private placements of equity and debt securities, securitizations in a variety of asset classes, public and private acquisitions and general corporate and commercial law matters.
공시 • Oct 30Vaxil Bio Ltd. announced that it expects to receive CAD 0.35 million in fundingVaxil Bio Ltd. announced a non brokered private placement to issue 2,456,140 units at an issue price of CAD 0.1425 for the proceeds of CAD 350,000 on October 29, 2025. Each Unit will consist of one common share of the Company ("Shares") and one common share purchase warrant of the Company ("Warrants"). Each Warrant will entitle the holder to acquire one Share at a price of CAD 0.19 per Share for a period of five years following the closing of the Offering. The closing of the Offering is subject to a number of conditions, including but not limited to, approval by the TSX Venture Exchange of the Offering. The Company expects the Offering to close on or around November 14, 2025. On the closing of the Offering, the Company has agreed to pay certain finders a cash commission of up to 8% of the gross proceeds of the Offering and non-transferrable Warrants. The Units, the Shares and Warrants comprising the Units and the Finders' Warrants will be subject to a hold period of four months and one day from their date of issue in accordance with applicable securities laws.
공시 • Apr 04Vaxil Bio Ltd. Announces Appointment of Daniel Bloch to the Audit CommitteeVaxil Bio Ltd. announced the Mr. Daniel Bloch, a current director of the Company has joined the audit committee, effective immediately. The audit committee now comprises Dr. Ari Kellen, Dr. Shawn Langer and Mr. Daniel Bloch, all independent directors. The board of directors remains unchanged, and comprises Mr. Gadi Levin (Chairperson and CEO), Dr. Ari Kellen (independent director), Dr. Shawn Langer (independent director) and Mr. Daniel Bloch (independent director).
공시 • Jan 17Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. On August 20, 2024, the companies entered into an amalgamation agreement pursuant to which Vaxil will acquire all of the issued and outstanding securities of Green Data in a reverse merger transaction. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data. Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on January 16, 2025.
공시 • Oct 07Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024.
공시 • May 28Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data.
공시 • Mar 06Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI. Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on March 4, 2024.
공시 • Jan 11Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI.
공시 • Aug 03+ 1 more updateVaxil Bio Ltd. Announces CFO ChangesVaxil Bio Ltd. announced, effective July 31, 2023, in order to reduce costs and preserve cash, Dr. Yuval Avnir, the Company’s CEO will be replaced by Mr. Gadi Levin, the Company’s current chairperson of the board and CFO. The Company further announces, effective July 31, 2023, the appointment of Mr. Alan Rootenberg, as the Company’s CFO. Mr. Rootenberg will be replacing Mr. Gadi Levin, who transitions from the CFO position to the CEO position. Mr. Rootenberg is a chartered professional accountant who has served as the Chief Financial Officer of a number of publicly traded companies listed on the NASDAQ, TSX, TSXV and CSE. These companies include biotechnology, mineral exploration, service technologies and cannabis research companies. He has also served as a director of a number of publicly traded companies. Mr. Rootenberg has a Bachelor of Commerce degree from the University of the Witwatersrand in Johannesburg, South Africa and received his CPA designation in Ontario, Canada.
공시 • Jan 05Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOXVAXIL BIO LTD. provided an update on the results of in vivo efficacy study for licensed P-Esbp-DOX, a novel anti-cancer drug, first disclosed in press release from October 12, 2021. Vaxil, together with Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev (BGU), have demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). The results of the current in vivo experiment, along with the previous in vivo experiments suggests that P-Esbp-DOX which combines the safe HPMA polymer, the high affinity E-selectin targeting peptide, and the commonly used chemotherapeutic drug doxorubicin, is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer. P-Esbp-DOX is an HPMA (N-(2-hydroxypropyl methacrylamide)) polymer conjugated with a high-affinity E-selectin-binding peptide and with the cytotoxic drug doxorubicin (DOX). Targeting E-selectin is relevant to diseases with inflammatory component and cancer, since E-selectin is expressed exclusively on inflamed blood vessels and play an important role in the development of inflammation, cancer and supports metastatic spread of cancer. Prof. Ayelet David’s previous work in cancer research demonstrated that a single dose therapy of P-Esbp-DOX is effective in decreasing the rate of tumor growth and prolonging the survival of mice bearing primary Lewis lung carcinoma (3LL) tumors and established melanoma (B16-F10) lung metastases. In the experiment, four groups of mice were treated, four days post intrasplenic inoculation of CT26 colorectal cancer cells, with a single dose of either P-Esbp-DOX or P-DOX (15 mg/kg DOX equivalence), or free DOX (8 mg/kg), or saline. The findings confirm the significant effectiveness of a single dose of P-Esbp-DOX over other treatments in mice with detected CRC liver metastases: The number of surviving mice at day 85 was: 3/7 (43%) for P-Esbp-DOX, 1/6 (17%) for free DOX, and 0/6 for P-DOX and saline. The survival medians were: 63 days for P-Esbp-DOX, 36.5 days for P-DOX, 30 days for free DOX, and 35 days for saline (p=0.003 for P-Esbp-DOX vs. control P-DOX). P-Esbp-DOX was well-tolerated at the dose administered, with no weight loss observed post treatment. In summary, this experiment, coupled with previous work, continues to demonstrate the important role this novel therapeutic approach could play in cancer at all stages. Vaxil is pursuing all necessary steps to initiate human clinical trials as soon as possible. As previously disclosed in the Company's press release from August 28, 2019, the Company entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the Company will pay BGU a royalty on sales.